Matthew Gline - 20 Sep 2024 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role
CEO, Director
Signature
By: /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline
Issuer symbol
ROIV
Transactions as of
20 Sep 2024
Net transactions value
-$23,513,624
Form type
4
Filing time
24 Sep 2024, 21:01:02 UTC
Previous filing
22 Aug 2024
Next filing
22 Oct 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ROIV Common Shares Tax liability $131,012 -10,945 -0.06% $11.97 18,303,800 20 Sep 2024 Direct F1
transaction ROIV Common Shares Options Exercise $5,967,500 +1,550,000 +8.5% $3.85 19,853,800 23 Sep 2024 Direct
transaction ROIV Common Shares Sale $23,382,600 -1,983,257 -10% $11.79 17,870,543 23 Sep 2024 Direct F2, F3
transaction ROIV Common Shares Other $5,967,512 -498,539 -2.8% $11.97 17,372,004 23 Sep 2024 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -1,550,000 -9.4% $0.000000 14,973,184 23 Sep 2024 Common Stock 1,550,000 $3.85 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
F2 The reporting person does not expect to sell additional shares of the Issuer in the near future.
F3 The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
F4 Represents the "net settlement" by the Issuer of options previously granted to the reporting person in order to satisfy the exercise price applicable to such options.
F5 Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).